Shreya Agarwal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shreya Agarwal has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Ionela Iacobas
Baylor College of Medicine
2 shared publications Joseph R. Stanek
Biostatistics Resource at Nationwide Children's Hospital Columbus Ohio USA
2 shared publicationsMichael E. Scheurer
Texas Children’s Cancer and Hematology Center
2 shared publicationsRosa Diaz
Texas Children's Hospital, Cancer and Hematology Center Baylor College of Medicine Houston Texas USA
2 shared publicationsSarah E. Sartain
Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine
2 shared publicationsValeria Smith
Texas Children's Hospital, Cancer and Hematology Center Baylor College of Medicine Houston Texas USA
2 shared publications
Latest Publications
- 27 September 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (1) , 7-15
Prevalence and Risk Factors for Venous Thromboembolism in People With Inherited Bleeding Disorders: An ATHNdataset Study
It is presumed that people with inherited bleeding disorders are protected against the risk of venous thromboembolism (VTE) but the supporting data regarding rates and risk factors for VTE in this population are lacking. The objectives of this study were to determine the VTE rates and risk factors in a cohort of individuals with inherited bleeding disorders. American Thrombosis and Hemostasis Network (ATHN) dataset was utilized for this study. The population of interest was individuals with an inherited bleeding disorder with a documented VTE. Data were collected regarding their bleeding disorder, demographics, type of VTE, and comorbidities. Data were summarized using standard descriptive analyses, and logistic regression analyses were used to identify risk factors. We identified a total of 49,151 individuals with inherited bleeding disorders in the ATHNdataset. A total of 388 new VTE (0.8%; 95% CI: 0.7, 0.9) were observed. Median age at VTE diagnosis was 27.5 years (IQR: 15.3–48.2). VTE rates were highest in prothrombin deficiency at 19% and relatively lower in hemophilia A and B at 0.4%. Within the hemophilia cohort, rates of VTE were higher in those with inhibitors ( p < 0.001). The VTE recurrence rate was 4.9% ( n = 19/388). On multivariable analysis, Black race (OR = 1.90), central venous line (CVL) (OR = 2.76), and cardiac comorbidity (OR = 16.86) were identified as risk factors for VTE. In summary, our results demonstrate that people with inherited bleeding disorders are not protected against VTE. Individual factors such as cardiac comorbidity and the presence of a CVL can increase the prothrombotic risk.
- 27 September 2025
- Published by Wiley in American Journal of Hematology
- Vol. 101 (1) , 7-15
Prevalence and Risk Factors for Venous Thromboembolism in People With Inherited Bleeding Disorders: An ATHNdataset Study
It is presumed that people with inherited bleeding disorders are protected against the risk of venous thromboembolism (VTE) but the supporting data regarding rates and risk factors for VTE in this population are lacking. The objectives of this study were to determine the VTE rates and risk factors in a cohort of individuals with inherited bleeding disorders. American Thrombosis and Hemostasis Network (ATHN) dataset was utilized for this study. The population of interest was individuals with an inherited bleeding disorder with a documented VTE. Data were collected regarding their bleeding disorder, demographics, type of VTE, and comorbidities. Data were summarized using standard descriptive analyses, and logistic regression analyses were used to identify risk factors. We identified a total of 49,151 individuals with inherited bleeding disorders in the ATHNdataset. A total of 388 new VTE (0.8%; 95% CI: 0.7, 0.9) were observed. Median age at VTE diagnosis was 27.5 years (IQR: 15.3–48.2). VTE rates were highest in prothrombin deficiency at 19% and relatively lower in hemophilia A and B at 0.4%. Within the hemophilia cohort, rates of VTE were higher in those with inhibitors ( p < 0.001). The VTE recurrence rate was 4.9% ( n = 19/388). On multivariable analysis, Black race (OR = 1.90), central venous line (CVL) (OR = 2.76), and cardiac comorbidity (OR = 16.86) were identified as risk factors for VTE. In summary, our results demonstrate that people with inherited bleeding disorders are not protected against VTE. Individual factors such as cardiac comorbidity and the presence of a CVL can increase the prothrombotic risk.
- Open Access
- 13 August 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (6)
Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
- 13 August 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (6)
Open AccessPlasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
- Open Access
- 5 June 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (7) , 459-469
Hospital acquired venous thromboembolism in children with sickle cell disease
Sickle cell disease (SCD) is well recognized as a hypercoagulablestate, however, it remains unclear whether a subgroup of children with SCD at higher risk of venous thromboembolic event (VTE) during hospitalization may benefit from thromboprophylaxis. Our objectives were to describe the clinical characteristics, outcomes and recurrence of hospital acquired VTE in patients with SCD younger than 21 years. This was a single center retrospective study. Data regarding demographics, reason for admission, location of VTE, risk factors like central venous catheter (CVC), intensive care unit (ICU) admission among others were extracted from electronic medical records over a 10-year study period (2011-2021). Recurrence of VTE at 1 and 5 years was assessed. Descriptive statistics were used as indicated. We identified a total of 20 VTE events over the 10-year study period. Six of these events occurred in those younger than 12 years of age. Fourteen (70%) VTE events occurred in the HbSS or HbS beta Thal0 genotypes compared to 6 (30%) in HbSC. Most common VTE was isolated pulmonary embolism (PE) (n = 10, 50%). VTE were most often associated with acute chest syndrome (ACS) (n = 14, 70%), ICU admissions (n = 10, 50%) and CVC (n = 5/9, 55%). One patient died from the VTE event. One patient with additional underlying risk factors had a recurrent VTE at 13 months. Our study suggests that ICU admission, ACS and presence of CVC increases the risk of VTE in children and young adults with SCD, but larger studies are indicated to validate our findings.
- 5 June 2024
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- Vol. 41 (7) , 459-469
Open AccessHospital acquired venous thromboembolism in children with sickle cell disease
Sickle cell disease (SCD) is well recognized as a hypercoagulablestate, however, it remains unclear whether a subgroup of children with SCD at higher risk of venous thromboembolic event (VTE) during hospitalization may benefit from thromboprophylaxis. Our objectives were to describe the clinical characteristics, outcomes and recurrence of hospital acquired VTE in patients with SCD younger than 21 years. This was a single center retrospective study. Data regarding demographics, reason for admission, location of VTE, risk factors like central venous catheter (CVC), intensive care unit (ICU) admission among others were extracted from electronic medical records over a 10-year study period (2011-2021). Recurrence of VTE at 1 and 5 years was assessed. Descriptive statistics were used as indicated. We identified a total of 20 VTE events over the 10-year study period. Six of these events occurred in those younger than 12 years of age. Fourteen (70%) VTE events occurred in the HbSS or HbS beta Thal0 genotypes compared to 6 (30%) in HbSC. Most common VTE was isolated pulmonary embolism (PE) (n = 10, 50%). VTE were most often associated with acute chest syndrome (ACS) (n = 14, 70%), ICU admissions (n = 10, 50%) and CVC (n = 5/9, 55%). One patient died from the VTE event. One patient with additional underlying risk factors had a recurrent VTE at 13 months. Our study suggests that ICU admission, ACS and presence of CVC increases the risk of VTE in children and young adults with SCD, but larger studies are indicated to validate our findings.
- 14 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (5) , OP2300314
Improving Time to Antibiotic Administration for Pediatric Oncology Patients With New-Onset Fever
PURPOSE Time to antibiotic administration (TTA) in <60 minutes for children with neutropenic fever presenting to an emergency room is associated with reduced incidence of sepsis and intensive care admission. As such, TTA is used as a national quality metric for pediatric oncology patients. At our center, in 2020, 19% of the hospitalized patients with a new fever encounter were receiving antibiotics in 90% in all pediatric patients with cancer with a new fever. METHODS A multidisciplinary team completed four Plan-Do-Study-Act cycles between March 2021 and September 2023. We implemented education initiatives, an updated handoff smartphrase guiding the on-call team, an antibiotic champion (AC) nursing role, a revised fever plan for handoff, a rapid-response team to address new fevers, and an algorithm for blood culture collection. Data were collected, analyzed, and reported biweekly with feedback sought for delays in TTA. RESULTS There was a total of 639 new fevers in 329 unique oncology patients. As of September 4, 2023, average TTA decreased from 89 minutes at baseline to 46.4 minutes for more than 12 months. The percentage of patients receiving first dose of antibiotic in <60 minutes also increased from 19% to 93.7%, which was sustained as well. The most effective interventions were creation of the AC role and streamlining the blood culture collection process. CONCLUSION This project demonstrates the importance of multidisciplinary involvement for providing optimal care. Specific implementation of targeted education, an AC role, and development of an algorithm streamlining the processes led to meaningful targeted improvements. Further analyses will explore the impact of these interventions on patient outcomes.
- 14 February 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 20 (5) , OP2300314
Improving Time to Antibiotic Administration for Pediatric Oncology Patients With New-Onset Fever
PURPOSE Time to antibiotic administration (TTA) in <60 minutes for children with neutropenic fever presenting to an emergency room is associated with reduced incidence of sepsis and intensive care admission. As such, TTA is used as a national quality metric for pediatric oncology patients. At our center, in 2020, 19% of the hospitalized patients with a new fever encounter were receiving antibiotics in 90% in all pediatric patients with cancer with a new fever. METHODS A multidisciplinary team completed four Plan-Do-Study-Act cycles between March 2021 and September 2023. We implemented education initiatives, an updated handoff smartphrase guiding the on-call team, an antibiotic champion (AC) nursing role, a revised fever plan for handoff, a rapid-response team to address new fevers, and an algorithm for blood culture collection. Data were collected, analyzed, and reported biweekly with feedback sought for delays in TTA. RESULTS There was a total of 639 new fevers in 329 unique oncology patients. As of September 4, 2023, average TTA decreased from 89 minutes at baseline to 46.4 minutes for more than 12 months. The percentage of patients receiving first dose of antibiotic in <60 minutes also increased from 19% to 93.7%, which was sustained as well. The most effective interventions were creation of the AC role and streamlining the blood culture collection process. CONCLUSION This project demonstrates the importance of multidisciplinary involvement for providing optimal care. Specific implementation of targeted education, an AC role, and development of an algorithm streamlining the processes led to meaningful targeted improvements. Further analyses will explore the impact of these interventions on patient outcomes.
- Open Access
- 8 August 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (11) , 1677-1684
Pregnancy‐related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data
Pregnancy and sickle cell disease (SCD) both individually carry a risk of thromboembolism (TE). Pregnancy in people with SCD may further enhance the prothrombotic effect of the underlying disease. The objectives of this study were to determine the rate and risk factors for arterial and venous thrombosis in pregnant people with SCD. Administrative claims data from the United States Centers for Medicare and Medicaid Service Analytic eXtract from 2006 to 2018 were used. The study population included people with SCD from the start of their first identified pregnancy until 1 year postpartum and a control cohort of pregnant people without SCD of similar age and race. Outcomes of interest were identified with ICD‐9 or 10 codes. Logistic regression analyses were used to analyze risk factors. We identified infant deliveries in 6388 unique people with SCD and 17 110 controls. A total of 720 venous thromboembolism (11.3%) and 335 arterial TE (5.2%) were observed in people with SCD compared to 202 (1.2%) and 95 (0.6%) in controls. People with SCD had an 8–11 times higher odds of TE compared to controls (p < .001). Within the SCD cohort, age, hemoglobin SS (HbSS) genotype, hypertension, and history of thrombosis were identified as independent risk factors for pregnancy‐related TE. Pregnancy‐specific factors (pre‐eclampsia, eclampsia, multigestational pregnancy) were not associated with TE. In conclusion, the risk of pregnancy‐related TE is considerably higher in people with SCD compared with controls without SCD. Hence, people with SCD, particularly those with multiple risk factors may be candidates for thromboprophylaxis during pregnancy and the postpartum period.
- 8 August 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (11) , 1677-1684
Open AccessPregnancy‐related thromboembolism in women with sickle cell disease: An analysis of National Medicaid Data
Pregnancy and sickle cell disease (SCD) both individually carry a risk of thromboembolism (TE). Pregnancy in people with SCD may further enhance the prothrombotic effect of the underlying disease. The objectives of this study were to determine the rate and risk factors for arterial and venous thrombosis in pregnant people with SCD. Administrative claims data from the United States Centers for Medicare and Medicaid Service Analytic eXtract from 2006 to 2018 were used. The study population included people with SCD from the start of their first identified pregnancy until 1 year postpartum and a control cohort of pregnant people without SCD of similar age and race. Outcomes of interest were identified with ICD‐9 or 10 codes. Logistic regression analyses were used to analyze risk factors. We identified infant deliveries in 6388 unique people with SCD and 17 110 controls. A total of 720 venous thromboembolism (11.3%) and 335 arterial TE (5.2%) were observed in people with SCD compared to 202 (1.2%) and 95 (0.6%) in controls. People with SCD had an 8–11 times higher odds of TE compared to controls (p < .001). Within the SCD cohort, age, hemoglobin SS (HbSS) genotype, hypertension, and history of thrombosis were identified as independent risk factors for pregnancy‐related TE. Pregnancy‐specific factors (pre‐eclampsia, eclampsia, multigestational pregnancy) were not associated with TE. In conclusion, the risk of pregnancy‐related TE is considerably higher in people with SCD compared with controls without SCD. Hence, people with SCD, particularly those with multiple risk factors may be candidates for thromboprophylaxis during pregnancy and the postpartum period.
- 2 February 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (3) , 318-327
Prenatal diagnosis of vascular anomalies
Vascular anomalies are rare disorders that encompass a group of lesions characterized by abnormal development of the lymphovascular system. Majority of these anomalies are present at birth and could potentially be detected during the prenatal period on imaging. This allows for early intervention and prompt management to improve outcomes. However, they can be difficult to diagnose, given the rarity and overlapping findings. In this review article, we provide a comprehensive overview of congenital vascular anomalies with a liberal use of images of recent cases at our center emphasizing prenatal imaging findings and the natural history of these conditions.
- 2 February 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 43 (3) , 318-327
Prenatal diagnosis of vascular anomalies
Vascular anomalies are rare disorders that encompass a group of lesions characterized by abnormal development of the lymphovascular system. Majority of these anomalies are present at birth and could potentially be detected during the prenatal period on imaging. This allows for early intervention and prompt management to improve outcomes. However, they can be difficult to diagnose, given the rarity and overlapping findings. In this review article, we provide a comprehensive overview of congenital vascular anomalies with a liberal use of images of recent cases at our center emphasizing prenatal imaging findings and the natural history of these conditions.
- Open Access
- 8 July 2022
- Published by Elsevier in Thrombosis Update
- Vol. 8, 100116
Downregulation of thrombomodulin-thrombin-activated protein C pathway as a mechanism for SARS-CoV-2 induced endotheliopathy and microvascular thrombosis
- 8 July 2022
- Published by Elsevier in Thrombosis Update
- Vol. 8, 100116
Open AccessDownregulation of thrombomodulin-thrombin-activated protein C pathway as a mechanism for SARS-CoV-2 induced endotheliopathy and microvascular thrombosis
- 28 March 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (6) , 889-895
Diffuse alveolar hemorrhage: An underreported complication of transplant associated thrombotic microangiopathy
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) and diffuse alveolar hemorrhage (DAH) are well recognized post-transplant complications that carry a high risk of mortality; however, the risk of DAH complicating the course of transplant patients with TA-TMA is not well understood. We conducted a ten-year retrospective study at our institution to determine the incidence of DAH in a cohort of pediatric patients with TA-TMA and described their presentation and outcomes. Additionally, autopsy slides, when available, were reviewed to assess for histological evidence of microvascular injury and alveolar hemorrhages. A total of 58 pediatric patients with TA-TMA were identified. Of these, 14 (24%) had DAH. Majority of DAH cases occurred within a week of TA-TMA diagnosis (n = 8, 57%, range 0-698 days). Mortality was 100% for patients with DAH and TA-TMA. Infections were found to be a significant risk factor for DAH in TA-TMA. Autopsy was performed in 11 of the 14 patients, and pulmonary slides were available for review in ten cases. 70% cases had pathological evidence of microvascular injury, concerning for pulmonary TA-TMA. We conclude that DAH is a potentially fatal complication in patients with TA-TMA and may be a result of pulmonary microangiopathy.
- 28 March 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (6) , 889-895
Diffuse alveolar hemorrhage: An underreported complication of transplant associated thrombotic microangiopathy
Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) and diffuse alveolar hemorrhage (DAH) are well recognized post-transplant complications that carry a high risk of mortality; however, the risk of DAH complicating the course of transplant patients with TA-TMA is not well understood. We conducted a ten-year retrospective study at our institution to determine the incidence of DAH in a cohort of pediatric patients with TA-TMA and described their presentation and outcomes. Additionally, autopsy slides, when available, were reviewed to assess for histological evidence of microvascular injury and alveolar hemorrhages. A total of 58 pediatric patients with TA-TMA were identified. Of these, 14 (24%) had DAH. Majority of DAH cases occurred within a week of TA-TMA diagnosis (n = 8, 57%, range 0-698 days). Mortality was 100% for patients with DAH and TA-TMA. Infections were found to be a significant risk factor for DAH in TA-TMA. Autopsy was performed in 11 of the 14 patients, and pulmonary slides were available for review in ten cases. 70% cases had pathological evidence of microvascular injury, concerning for pulmonary TA-TMA. We conclude that DAH is a potentially fatal complication in patients with TA-TMA and may be a result of pulmonary microangiopathy.
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29510
Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions
Background: Chylothorax can be a presenting symptom of complex lymphatic anomaly in children and is associated with significant respiratory morbidity. Historically, the traditional pharmacological treatment has been octreotide. There are several treatments that have been utilized in the past few years including sirolimus; however, data regarding their efficacy and outcomes is limited. Furthermore, sirolimus has proven efficacy in complex vascular malformations, and hence, its utility/efficacy in infantile primary chylous effusions warrants further investigation.Methods: In this retrospective study at Texas Children's Hospital, data were extracted for all infants with chylothorax who were treated with sirolimus between 2009 and 2020. Details regarding underlying diagnosis, comorbidities, and number of days from sirolimus initiation to resolution of effusion were collected.Results: Initially a total of 12 infants were identified. Among them, seven patients had complete data and were included in the study. Reasons for chylous effusions include presumed complex lymphatic anomaly, generalized lymphatic anomaly, and complex congenital lymphatic anomaly. The mean duration of sirolimus treatment needed for chest tube removal was 16 days, with a median of 19 days and range of 7–22 days. No patients had progression of effusions while on sirolimus.Conclusion: With close monitoring, sirolimus appears to be an effective therapy for pediatric lymphatic effusions even in critically ill infants. The study also demonstrates shorter duration of chest tube requirement after initiation of sirolimus compared to previous studies. Larger multi‐institutional studies are needed to further support our findings.
- 10 December 2021
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (2) , e29510
Sirolimus efficacy in the treatment of critically ill infants with congenital primary chylous effusions
Background: Chylothorax can be a presenting symptom of complex lymphatic anomaly in children and is associated with significant respiratory morbidity. Historically, the traditional pharmacological treatment has been octreotide. There are several treatments that have been utilized in the past few years including sirolimus; however, data regarding their efficacy and outcomes is limited. Furthermore, sirolimus has proven efficacy in complex vascular malformations, and hence, its utility/efficacy in infantile primary chylous effusions warrants further investigation.Methods: In this retrospective study at Texas Children's Hospital, data were extracted for all infants with chylothorax who were treated with sirolimus between 2009 and 2020. Details regarding underlying diagnosis, comorbidities, and number of days from sirolimus initiation to resolution of effusion were collected.Results: Initially a total of 12 infants were identified. Among them, seven patients had complete data and were included in the study. Reasons for chylous effusions include presumed complex lymphatic anomaly, generalized lymphatic anomaly, and complex congenital lymphatic anomaly. The mean duration of sirolimus treatment needed for chest tube removal was 16 days, with a median of 19 days and range of 7–22 days. No patients had progression of effusions while on sirolimus.Conclusion: With close monitoring, sirolimus appears to be an effective therapy for pediatric lymphatic effusions even in critically ill infants. The study also demonstrates shorter duration of chest tube requirement after initiation of sirolimus compared to previous studies. Larger multi‐institutional studies are needed to further support our findings.
- Open Access
- 25 September 2021
- Published by Wiley
SIROLIMUS EFFICACY IN THE TREATMENT OF CRITICALLY- ILL INFANTS WITH CHYLOUS EFFUSIONS
Background: While rare in children, chylothorax is a significant cause of respiratory morbidity and can lead to malnutrition and immunodeficiency. Historically, the traditional pharmacological treatment has been octreotide. There are several treatments that have been utilized in the past few years including sirolimus, however data regarding their efficacy and outcomes is limited. Furthermore, sirolimus has proven efficacy in complex vascular malformations, and hence, its utility/efficacy in pediatric chylous effusions warrants further investigation. Methods: In this retrospective study at Texas Children’s Hospital, data were extracted for all patients with chylothorax who were treated with sirolimus between 2009 and 2020. Details regarding underlying diagnosis, co-morbidities and number of days from sirolimus initiation to resolution of effusion were collected. Descriptive statistics were used to analyze the study cohort. Results: Initially a total of twelve infants were identified. Among them, seven patients had complete data and were included in the study. The mean duration of sirolimus treatment needed for chest tube removal was 16 days, with a median of 19 days and range of 7- 22 days. Chest tube output corresponded with sirolimus serum trough levels and trended down prior to chest tube removal. Conclusion: With close monitoring, sirolimus is a safe and effective therapy for pediatric lymphatic effusions even in critically-ill infants. The study also demonstrates shorter duration of chest tube requirement after initiation of sirolimus compared to previous studies. Our conclusion is based on a small case series due to the rare incidence of the condition.
- 25 September 2021
- Published by Wiley
Open AccessSIROLIMUS EFFICACY IN THE TREATMENT OF CRITICALLY- ILL INFANTS WITH CHYLOUS EFFUSIONS
Background: While rare in children, chylothorax is a significant cause of respiratory morbidity and can lead to malnutrition and immunodeficiency. Historically, the traditional pharmacological treatment has been octreotide. There are several treatments that have been utilized in the past few years including sirolimus, however data regarding their efficacy and outcomes is limited. Furthermore, sirolimus has proven efficacy in complex vascular malformations, and hence, its utility/efficacy in pediatric chylous effusions warrants further investigation. Methods: In this retrospective study at Texas Children’s Hospital, data were extracted for all patients with chylothorax who were treated with sirolimus between 2009 and 2020. Details regarding underlying diagnosis, co-morbidities and number of days from sirolimus initiation to resolution of effusion were collected. Descriptive statistics were used to analyze the study cohort. Results: Initially a total of twelve infants were identified. Among them, seven patients had complete data and were included in the study. The mean duration of sirolimus treatment needed for chest tube removal was 16 days, with a median of 19 days and range of 7- 22 days. Chest tube output corresponded with sirolimus serum trough levels and trended down prior to chest tube removal. Conclusion: With close monitoring, sirolimus is a safe and effective therapy for pediatric lymphatic effusions even in critically-ill infants. The study also demonstrates shorter duration of chest tube requirement after initiation of sirolimus compared to previous studies. Our conclusion is based on a small case series due to the rare incidence of the condition.